National guideline for the management of donovanosis (granuloma inguinale). Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D000075202:Contraindications; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D005832:Genital Diseases, Male / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D005839:Gentamicins / Q000627:therapeutic use; D006100:Granuloma Inguinale / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D014456:Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D002939:Ciprofloxacin; D017963:Azithromycin; D004318:Doxycycline